Science

Apr 26, 2025, 09:19

Myeloma Paper of the Day, April 26th, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Phase 2 randomized study of modakafusp alfa in patients with relapsed/refractory myeloma finds ORRs were 32% and 41% at 120 and 240 mg arms; median PFS 4.1 and 5.3 months; ORRs higher in patients without prior-BCMA therapy (46% vs. 29%).”

“A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma”

Authors: Sarah Holstein, Shebli Atrash, Hira Mian, Meletios Athanasios Dimopoulos, Fredrik Schjesvold, Shuli Li, Allison Nelson, Dasha Cherepanov, Xavier Parot, Dan Vogl et al.

More posts featuring Robert Orlowski.

Allison Nelson cancer Dan Vogl Dasha Cherepanov Fredrik Schjesvold Hira Mian Meletios-Athanasios Dimopoulos multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski RRMM Sarah Holstein Shebli Atrash Shuli Li Xavier Parot

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

Happy Birthday OncoDaily!

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer